Abstract: A pharmaceutical composition for use in the treatment of chronic Graft-versus-host diseases as well as autoimmune diseases, in particular for the treatment of systemic lupus erythematosus containing as an active ingredient at least one compound of the formulae 1 or 2 ##STR1## the latter being present per se or in the form of a physiologically tolerable salt.The invention also relates to a dosage unit form of said pharmaceutical composition and a method of treating chronic Graft-versus-host diseases as well as autoimmune diseases, in particular systemic lupus erythematosus.

Abstract: This invention relates to a method for treating or preventing hemorrhoids, comprising administering to a susceptible animal a 5-hydroxytryptamine.sub.2 (5-HT.sub.2) receptor antagonist at an anti-hemorrhoidally effective therapeutic dose.

Abstract: Presented are compositions for disinfection of the skin. The composition is characterized in that it contains in an aqueous medium; 0.5 to 10 w/v % of chlorhexidine digluconate, 5 to 25 w/v % of polyoxyethylene alkyl ether, 1 to 5 w/v % of fatty acid diethanolamide, 1 to 5 w/v % of alkyldimethylamine oxide, and macrogol at less than 10 w/v %. The polyoxyethylene alkyl ether and macrogol may be replaced with 10 to 35 w/v % of polyoxyethylene alkylphenyl ether. The composition may further contain 5 w/v % or lower polyoxyethylene lanolin.Since the composition will not solidify even when its solvent is evaporated, the plugging of the outlet opening of the dispenser will be avoided.

Abstract: There is described the production of a pharmaceutical composition for the eatment of autoimmune diseases, whereby multiple sclerosis is excluded. As active materials, there are thereby used compounds of the general formula I ##STR1## in which R.sub.1 represents alkyl with 12 to 18 carbon atoms, R.sub.2 alkyl with 1 to 8 carbon atoms and R.sub.3 H or alkyl with 1 to 3 carbon atoms.

Abstract: A method for treating or preventing alopecia which is induced by an antineoplastic compound is disclosed which is based on the administration of a particular tellurium or selenium derivative to a patient prior to the administration of a antineoplastic agent to said patent.

Abstract: The invention relates to a composition intended for the treatment of skin aging, containing, in a physiologically acceptable medium, at least one salicylic acid derivative corresponding to the formula: ##STR1## in which: R represents a saturated aliphatic chain or an unsaturated chain bearing one or more conjugated or unconjugated double bonds, it being possible for the chains to be substituted with one or more halogen atoms as well as with trifluoromethyl groups, with one or more hydroxyl groups in free form or a form esterified by an acid, or alternatively with a carboxyl group, free or esterified by a lower alcohol; andR' represents a hydroxyl group or an ester group of formula: ##STR2## where R.sub.1 is a saturated or unsaturated aliphatic group.

Abstract: Ulcerative conditions of the gastro-intestinal tract, e.g., antiinflammatory-drug-induced ulcers, are treated or prevented by the administration of a potassium channel activator. Methods and combination products are also disclosed for the treatment of inflammatory conditions without causing ulceration of the gastrointestinal tract.

Abstract: A pharmaceutical composition comprising a non-peptide type angiotension II receptor antagonist is useful for the treatment of hyperuricemia.

Abstract: There is described finely divided nedocromil sodium, comprising a therapeutically effective proportion of individual particles capable of penetrating deep into the lung, characterized in that a bulk of the particles which is both unaggolomerated and unmixed with a coarse carrier, is sufficiently free flowing to be filled into capsules on an automatic filling machine and to empty from an opened capsule in an inhalation device.There is also described a method of making the fine particles and pharmaceutical formulations containing them.

Abstract: Provided is a method of treating humans or animals suffering from a condition or disease characterized by excessive collagen destruction, which comprises administering to said human or animal an effective amount of a 12a-deoxytetracycline represented by the following general formula ##STR1## The method is effective in the treatment of various articular diseases characterized by excessive collagen destruction.

Abstract: A topical composition which enhances the maintenance of penis erection is disclosed. An effective dosage of a peripheral vasodilator, an absorption enhancer and, optionally, a vasoconstrictor and an alpha receptor blocker are combined with a pharmacologically acceptable topical vehicle to produce the composition.

Abstract: The invention relates to a cosmetic composition comprising a mixture of(a) betaine,(b) ATP or an ATP generating system,(c) a magnesium salt, and(d) a potassium salt,in a cosmetically acceptable vehicle for topical administration and to a method for counteracting aging of the skin in a living human which utilizes the new composition.

Abstract: Methods for treating and preventing late-phase allergic reactions with misoprostol in a pharmaceutically acceptable excipient are provided. Tablet forms of misoprostol may be administered at doses of between 100 .mu.g and 300 .mu.g. The preparation may be administered alternatively as an aerosol. Late-phase respiratory and cutaneous reactions to dust mites, food and occupational allergens, pollen, weeds, grass, drugs, animal dander and chemicals may be treated with the described misoprostol-containing agents. Urticaria, contact dermatitis, asthma, allergic rhinitis and anaphylaxis are conditions which may be treated according to the presently disclosed methods and pharmaceutical agents.

Abstract: Compositions of retinoic acids and tocopherols which may be applied topically without producing retinoic acid-induced skin irritation.

Abstract: 1. An estradiol percutaneous administration preparation comprising:(1) a (A-B) nX or (A-B) n-A type elastomer wherein A is substantially monovinyl-substituted aromatic compound polymer block, B is substantially a conjugated diolefin copolymer block, n is an integer of 3-7, and X is a residue derived from a polyfunctional compound combined with n of polymer chain (A-B),(2) crotamiton and(3) a super absorbent polymer, the preparation further comprising estradiol as the medicinal ingredient and exhibiting sufficient medicinal efficacy without causing rubefaction, rashes and the like.

Abstract: Zwitterionic compounds selected from:taurine (2-aminoethanesulphonic acid),2(N-morpholino)ethanesulphonic acid (MES),N-(2-acetamido)iminodiacetic acid (ADA),piperazine-N,N'bis(2-ethanesulphonic acid (PIPES),N-(2-acetamido)-2-aminoethanesulphonic acid (ACES),N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES),3-(N-morpholino)propanesulphonic (MOPS),N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES),N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES),N-2-hydroxyethylpiperazine-N'3-propanesulphonic acid (H)EPPS),2-(cyclohexylamino)ethanesulphonic acid (CHES) or 3-(cyclohexylamino)propanesulphonic acid (CAPS),and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter alia to enhanced leukotriene inactivation.

Abstract: A method of treating comatose patients or near-comatose patients to increase their arousal and alertness as measured by the Glascow Coma Score by administering effective amounts of an adenosine receptor antagonist and a GABA agonist, either concomitantly in any order including simultaneously, or by administering an adenosine receptor antagonist as the sole active agent. The methods of administration are intravenous bolus or drip injection, subcutaneous injection or orally.

Abstract: A method of maintaining and/or enhancing tissue or plasma levels of glutathione is provided. Treatment of a mammal with a supranormal amount of glutamine, or a glutamine equivalent, prevents the reduction in tissue glutathione levels associated with exposure of the mammal to a compound capable of oxidative injury to the tissue. Such compounds may be drugs such as chemotherapeutic agents. Administration of a supranormal amount of glutamine or a glutamine equivalent after exposure of a mammal to a compound capable of oxidative injury to the tissue can ameliorate or prevent injury. Treatment of a mammal with glutamine or a glutamine equivalent can also reduce or prevent starvation- or radiation-associated oxidative damage in the tissues.

Abstract: (A) a diacylated dopamine derivative represented by the formula (I): ##STR1## wherein R.sup.1 represents an alkyl group having 3 to 7 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, substituted or unsubstituted phenyl group or a substituted or unsubstituted nitrogen-containing heterocyclic group; and R.sup.2 represents a hydrogen atom or a lower alkyl group; or a salt thereof; and(B) one or more compounds selected from lactic acid esters, fatty acid monoglycerides and higher alcohols; optionally together with(C) an unsaturated fatty acid monohydric alcohol ester. This preparation has a sustained effect, a high skin permeability and a low skin irritativeness.

Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.